It led to kidney cancer progression and diminished the effect of the anti-PD1 antibody therapy via at least two distinct mechanisms: a direct mechanism to tumor progression and inhibition of CD8+ T cell infiltration into the tumor. This evidence concerns the gene CD8A and kidney cancer.